Vyvanse is the page in the ADHD cost cluster where the numbers moved the most. Generic lisdexamfetamine is now approved and widely marketed, which turned a drug that used to cost roughly $400 a month into one that can cost under $60 a month, but only if you get the coupon, the pharmacy and the stock lined up at the same time.
This guide covers cash prices researched fresh on September 3, 2026, using the CMS NADAC acquisition-cost file effective August 19, 2026 alongside published retail prices. It also covers two things that quietly cost cash payers money on this specific drug: the Schedule II rule that stops you from moving a prescription after the fact, and a supply shortage that is still open at the FDA. If you are comparing across the cluster, this is the lisdexamfetamine page, and Concerta and Ritalin are the methylphenidate pages with a completely different price structure.
What Does Vyvanse Cost Without Insurance?
Prices below are published cash prices from the Drugs.com price guide read on September 3, 2026, plus Cost Plus Drugs’ own listed price for the non-stimulant it does carry. “Low” is the best published price including a free discount card, “Average” is the midpoint of the published range, and “High” is the top of the no-coupon cash range.
| Product / form | Low | Average | High |
|---|---|---|---|
| Generic lisdexamfetamine, 30 capsules | $55.53 | $242.21 | $255.48 |
| Generic lisdexamfetamine, 90 capsules | $336.51 | $689.20 | $1,041.89 |
| Brand Vyvanse, 30 capsules | $379.49 | $395.34 | $411.19 |
| Atomoxetine, non-stimulant generic (Cost Plus) | $13.21 | $13.21 | $432.00 retail elsewhere |
The Tier 1 anchor underneath those retail numbers is the CMS NADAC file, which reports what pharmacies actually pay to buy the drug. In the file effective August 19, 2026, generic lisdexamfetamine capsules cost pharmacies $2.60 to $2.81 per capsule depending on strength, which is $77.91 to $84.38 for a 30-count fill. Brand Vyvanse is essentially flat across every strength at about $12.34 to $12.36 per capsule, or roughly $370 for 30 capsules.
Read those two datasets together and the picture is clear. A cash payer handing over $228.93 for 30 generic capsules is paying roughly three times what the pharmacy paid for them, and the $55.53 discount-card price is close to, or slightly below, acquisition cost. That is normal for coupon pricing and it is why the coupon is not optional on this drug.
One form-specific trap: chewable tablets are a different price tier. NADAC puts generic lisdexamfetamine chewables at $3.36 to $4.39 per tablet on the same August 19, 2026 file, which works out to $100.66 to $131.78 per 30 tablets, meaningfully above the capsule. Brand chewables price like brand capsules, at about $12.35 each.
Drugs.com’s own summary of its Vyvanse page states a full spread of $55.53 to $411.19 across doses and pharmacies, which brackets both the generic and brand rows above. Where sources disagree, the disagreement is about coupons rather than about the drug: the no-coupon price guide shows $228.93 and up for the generic, while the coupon-aggregator rows on the same site show $55.53 to $78.93 for the same 30 capsules on the same day.
What Drives the Price
Brand versus generic
This is the whole ballgame. FDA’s Drugs@FDA database lists roughly 19 approved generic lisdexamfetamine product lines from about 15 sponsors, including Teva, Sandoz, Hikma, Sun, Apotex, Granules, Lannett, SpecGx and Rhodes, covering both capsules and chewable tablets. That many filers is what pushed acquisition cost from about $12.35 a capsule to about $2.65. Whether a generic is appropriate for you is a clinical question for your prescriber, not a cost question.
Capsule versus chewable tablet
As above, the chewable runs 25 to 70 percent higher than the capsule at acquisition cost. If your prescription is written for a chewable, that is a different price conversation than a capsule prescription.
Schedule II dispensing rules
Lisdexamfetamine is a Schedule II controlled substance. There are no automatic refills, and Schedule II prescriptions generally cannot be transferred from one pharmacy to another after they are on file. Practically, that means the ordinary cash-payer tactic of calling around after you have the script does not work here. You have to compare prices first, then have the prescriber send the prescription to the winner.
The open shortage
FDA’s drug shortage database, updated September 3, 2026, still shows lisdexamfetamine capsules in a current shortage that was first posted July 14, 2023. Takeda (the brand holder) and essentially every generic filer are listed with active entries, including Hikma and SpecGx updated in mid to late August 2026 and Elite Laboratories, Teva and Lannett updated September 1, 2026. Several entries cite a shortage of an active ingredient. For a cash payer this matters because the pharmacy with the best price is often not the pharmacy with stock, and the Schedule II rule above means guessing wrong is expensive in time.
Pharmacy and discount platform
The same 30-count fill priced between $55.53 and $255.48 on one day at one source. Chain-level cash prices for controlled stimulants are volatile and are not published as stable rate cards, so treat any single quote as a snapshot.
Cash Price vs. Insurance
Unlike most brand drugs in this category, there is no manufacturer copay card doing the heavy lifting for Vyvanse. The Drugs.com Vyvanse page found no active manufacturer promotion as of September 3, 2026, and the assistance it does list is charitable rather than commercial: the HealthWell Foundation copay program and Rx Outreach, a nonprofit mail-order pharmacy. Takeda separately runs Help at Hand, a financial needs-based program that provides its medicines free to eligible uninsured and underinsured patients, though you have to confirm current product eligibility with the program directly.
That absence changes the calculus. On drugs where a copay card exists, insured patients usually beat cash payers badly. Here, an insured patient with a high deductible and a cash payer with a good discount card can land in roughly the same place, and the cash payer sometimes wins outright, because a $55 to $80 generic fill is often below a specialty or non-preferred copay tier.
Two cautions. Discount-card prices do not count toward a deductible or out-of-pocket maximum, so if you expect to hit either this year, running the fill through insurance may be worth more than the coupon savings. And a few pharmacies decline third-party discount cards on Schedule II drugs, so confirm by phone before the prescription is sent.
How to Pay Less
Ask whether the generic is on the table. The gap between $55.53 and $411.19 for 30 capsules is the single largest cost decision on this page. Raise it with your prescriber before the script is written, since a brand-name prescription is harder to change once it is in the pharmacy’s queue.
Compare at least two discount cards before the script is sent. Card platforms price the same drug differently, sometimes by a factor of four. Our comparison of the two biggest, GoodRx vs. SingleCare, walks through how to run the same strength and quantity through both, and the fair price checker gives you a sanity range before you call.
Call the pharmacy about stock and price in the same call. Given the open shortage and the no-transfer rule, ask two questions at once: do you have this strength in stock, and what is the cash price with this discount card. Only then have the prescriber send it.
Ask about a larger quantity. Drugs.com’s price guide shows 90-capsule quantities from $336.51, which is $3.74 per capsule against $7.63 per capsule at a 30-count fill. Schedule II rules limit how a longer supply can be written and filled, so this is a question for your prescriber and pharmacist rather than something you can arrange yourself.
Separate the drug cost from the visit cost. A stimulant prescription requires ongoing prescriber visits, and those are often the larger annual line item. See psychiatrist cost and ADHD testing cost for what that side runs, and free and sliding-scale clinics if the visits are the part you cannot cover.
Do not let an unaffordable bill sit. If a pharmacy or clinic bill has already gone unpaid, read how to negotiate medical bills before it moves to collections.
The Bottom Line
As of September 3, 2026, a cash payer’s realistic range on lisdexamfetamine is about $55 to $85 per 30 capsules with the generic and a discount card, roughly $229 to $255 for the generic without one, and $379 to $411 for brand Vyvanse. The generic decision, the coupon and the pharmacy choice are worth several hundred dollars a month between them.
Act before the prescription is written, not after. Because this is a Schedule II drug in an open FDA shortage, the ability to shop disappears the moment the script lands at a pharmacy. If you are also comparing extended-release methylphenidate, Concerta has a far cheaper generic tier, while Strattera, Qelbree and guanfacine are non-stimulants that carry none of these dispensing restrictions. For the other amphetamine, see Adderall cost without insurance.